Beijing Anweison Biopharmaceutical

Beijing Anweison Biopharmaceutical is a clinical-stage biotechnology company based in China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on targeting key inflammatory pathways, including the IL-17 and IL-4/IL-13 axes, to treat conditions such as psoriasis and atopic dermatitis. Their lead programs include both small molecule inhibitors and monoclonal antibodies designed to provide superior efficacy and safety profiles compared to existing treatments. Anweison leverages its internal R&D capabilities to advance a robust pipeline through clinical development in the Chinese market.